Partial Retraction

@article{Silverman2011PartialR,
  title={Partial Retraction},
  author={Robert H. Silverman and Jaydip Das Gupta and Vincent C. Lombardi and Francis W. Ruscetti and Maximilian Pfost and Kathryn S. Hagen and Daniel L. Peterson and Sandra K. Ruscetti and Rachel Bagni and Cari Petrow-Sadowski and Bert Gold and Michael Dean and Judy A. Mikovits},
  journal={Science},
  year={2011},
  volume={334},
  pages={176 - 176}
}
[This retracts the article doi: 10.1590/s0004-2803.201900000-03]. 

Conference highlights of the 15th international conference on human retrovirology: HTLV and related retroviruses, 4-8 june 2011, Leuven, Gembloux, Belgium

The aim of this review is to distribute the scientific highlights of the presentations as analysed and represented by experts in specific fields of epidemiology, clinical research, immunology, animal models, molecular and cellular biology, and virology.

Xenotropic murine leukemia virus–related virus does not pose a risk to blood recipient safety

The prevalence of the virus among blood donors and, if present, its transmissibility by transfusion need to be defined.

Recombinant origin, contamination, and de-discovery of XMRV.

Main neuroendocrine features, diagnosis and therapeutic possibilities in the chronic fatigue syndrome, an underdiagnosed entity.

The management of the disease is based on cognitive behavioral therapy, graded exercise therapy and pacing, and medication plays a minor role in therapy.

Problems with precaution: the transfusion medicine experience

The findings indicate that transfusion transmission mitigation strategies have become increasingly aggressive in the face of theoretical risks and policy-makers should consider the implementation of frameworks to guide the appropriate application of precaution in transfusion medicine in the future.

Development and application of a high‐throughput microneutralization assay: lack of xenotropic murine leukemia virus–related virus and/or murine leukemia virus detection in blood donors

XMRV and other related MLVs have been described with chronic fatigue syndrome and certain types of prostate cancer, and several laboratories have utilized microneutralization assays as a surrogate marker for detection of anti‐MLV serologic responses.

The scientific method at work: xenotropic murine leukemia virus–related virus is neither a cause of chronic fatigue syndrome nor a threat to the blood supply

The events that have transpired over the past 2 years regarding the clinical relevance of xenotropic murine leukemia virus–related virus (XMRV) have shown that the method of scientific investigation first described 400 years ago is very much alive and well today.

In-Depth Investigation of Archival and Prospectively Collected Samples Reveals No Evidence for XMRV Infection in Prostate Cancer

Analysis of prostate cancer tissues and plasma from a prospectively collected cohort of 39 patients as well as archival RNA and prostate tissue from the original 2006 study reveal no association between XMRV and prostate cancer, and underscore the conclusion that X MRV is not a naturally acquired human infection.

Failure to Detect XMRV-Specific Antibodies in the Plasma of CFS Patients Using Highly Sensitive Chemiluminescence Immunoassays

It is concluded that the gammaretrovirus xenotropic murine leukemia virus-related retrovirus (XMRV) is not present in any human individual tested by us, regardless of CFS or healthy control.

Advances in molecular diagnostic testing for central nervous system infections

Progress has been made in the clinical validation and international recommendation of PCR-based tests for CNS infections, and Sequencing techniques present the most dynamic field, although significant ongoing challenges persist.